26 results on '"MacGregor G."'
Search Results
2. EPS1.07 Impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on Aspergillus fumigatus serology in adults with cystic fibrosis
3. First neutrino observations from the Sudbury Neutrino Observatory
4. 264: CF Active—Introducing alternative exercise professionals to support work done by clinicians in enhancing exercise habits of people with CF
5. Empowerment of individuals to reduce cardiovascular disease
6. 62 Correlated changes in inflammation biomarkers from a phase 1 study of acebilustat in adult cystic fibrosis patients
7. WS13.6 GLPG1837 in subjects with cystic fibrosis (CF) and the G551D mutation: results from a phase II study (SAPHIRA1)
8. 250 Patient-reported outcomes among patients (pts) with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor (IVA) compared with those homozygous for the F508del-CFTR mutation
9. ePS02.1 Advanced care planning and thinking ahead in cystic fibrosis: a quality improvement pilot project for adults with cystic fibrosis
10. 126 A phase 1 clinical study of CTX-4430 in cystic fibrosis patients
11. 297 Health care professionals’ appreciation of the challenges of concordance to therapies in CF
12. 148 The influence of moulds as an independent risk factor for decreasing lung function in cystic fibrosis
13. Promoting weight gain with olanzapine in underweight adults with cystic fibrosis
14. Can modern nebulisers improve patient outcomes?
15. PRS31 Modelling Survival of People with Cystic Fibrosis (PWCF) Aged ≥12 YEARS Homozygous for the F508DEL Mutation Treated with Ivacaftor/Tezacaftor/Elexacaftor and Ivacaftor (IVA/TEZ/ELX).
16. PRS2 Modelling Survival of People with Cystic Fibrosis (PWCF) Aged ≥12 YEARS Heterozygous for the F508DEL Mutation with a Minimal Function Mutation Treated with Ivacaftor/Tezacaftor/Elexacaftor and Ivacaftor (IVA/TEZ/ELX).
17. 496 A longitudinal study of bone mineral density change in adults with Cystic Fibrosis
18. P362 Vitamin A deficiency in the West of Scotland Adult CF Centre.
19. P195 Vaping and cystic fibrosis: current perceptions and future directions.
20. Burning questions.
21. PO46 Young women with breast cancer do well following immediate breast reconstruction in a networked regional-tertiary service.
22. Characteristics of a (Na(plus)(minus)K(plus) )(minus)ATPase inhibitor in extracts of tea
23. P110 Maintaining equity and quality of cystic fibrosis care: a roadmap for Scotland.
24. EPS10.08 LONGITUDE: an observational study of the long-term effectiveness of ELX/TEZ/IVA in people with CF using data from the UK CF Registry — preliminary results from the subgroup aged 6–11 years.
25. Maxi-K channels contribute to urinary potassium excretion in the ROMK-deficient mouse model of Type II Bartter's syndrome and in adaptation to a high-K diet.
26. 154 Morbidity and mortality following radical radiotherapy treatment for non-small cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.